| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ITGaE |
| Uniprot No | P38570 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 57-171aa |
| 氨基酸序列 | SPRTKRTPGPLHRCSLVQDEILCHPVEHVPIPKGRHRGVTVVRSHHGVLI CIQVLVRRPHSLSSELTGTCSLLGPDLRPQAQANFFDLENLLDPDARVDT GDCYSNKEGGGEDDV |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ITGaE(整合素αE亚基，CD103)重组蛋白研究的3篇示例参考文献(内容为模拟示例，具体文献需根据实际检索补充)：
---
1. **文献名称**：*"Recombinant ITGaE/CD103 protein modulates T cell adhesion in colorectal cancer microenvironment"*
**作者**：Smith A, et al.
**摘要**：研究利用重组ITGaE蛋白，解析其在肿瘤微环境中与E-cadherin的互作机制，发现其可增强肿瘤浸润T细胞的黏附能力，为免疫治疗提供新靶点。
2. **文献名称**：*"Expression and functional characterization of ITGaE-Fc fusion protein in mucosal immunity"*
**作者**：Chen L, et al.
**摘要**：通过构建ITGaE-Fc重组融合蛋白，验证其与β7整合素结合的特异性，并证明其在肠道黏膜免疫中调控淋巴细胞归巢的作用。
3. **文献名称**：*"Structural analysis of ITGaE ectodomain reveals key epitopes for antibody development"*
**作者**：Wang Y, et al.
**摘要**：利用重组ITGaE胞外域蛋白解析其晶体结构，鉴定出与自身免疫疾病相关的抗原表位，为靶向抗体设计提供结构基础。
---
如需真实文献，建议通过PubMed或Web of Science检索关键词：**"ITGaE recombinant protein"** 或 **"CD103 integrin expression"**，并筛选近5年内的实验性研究。
**Background of ITGaE Recombinant Protein**
Integrin alpha E (ITGaE), also known as CD103. is a cell surface receptor that plays a critical role in mediating cell-cell and cell-extracellular matrix interactions. As a subunit of the αEβ7 integrin heterodimer, ITGaE pairs exclusively with the β7 subunit to form a receptor predominantly expressed on immune cells, including intraepithelial lymphocytes (IELs), mucosal T cells, and regulatory T cells (Tregs). This integrin binds to E-cadherin, a cell adhesion molecule expressed on epithelial cells, facilitating lymphocyte retention and function in epithelial tissues, particularly in the gut, skin, and lungs.
The ITGaE-β7 integrin is essential for maintaining mucosal immunity and immune homeostasis. It supports T-cell activation, trafficking, and retention in epithelial barriers, enabling targeted immune responses against pathogens while regulating excessive inflammation. Dysregulation of ITGaE has been linked to autoimmune diseases, chronic inflammatory conditions (e.g., inflammatory bowel disease), and cancer progression, where altered integrin expression may influence immune evasion or metastasis.
Recombinant ITGaE protein is produced using biotechnological methods, such as mammalian or insect cell expression systems, to ensure proper post-translational modifications and functional fidelity. This engineered protein retains the ligand-binding capacity and structural features of native ITGaE, making it valuable for *in vitro* and *in vivo* studies. Researchers utilize ITGaE recombinant proteins to investigate integrin-mediated signaling pathways, screen therapeutic agents (e.g., monoclonal antibodies targeting αEβ7), or develop biomarkers for inflammatory and oncologic diseases. Its applications extend to immunotherapy research, particularly in designing strategies to modulate tissue-specific immune responses or enhance anti-tumor immunity.
Overall, ITGaE recombinant protein serves as a crucial tool for advancing understanding of mucosal immunology and developing targeted therapies for immune-related disorders.
×
